FELIPE VIEIRA RODRIGUES MACIEL

Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 12
  • conferenceObject
    Splenic Diffuse Red Pulp Small B Cell Lymphoma: Transformation To Diffuse Large Cells B Lymphoma
    (2013) BEZERRA, Evandro Dantas; FONTENELE, Leila Patricia; PEREIRA, Juliana; LAGE, Luis Alberto de Padua Covas; MACIEL, Felipe; BARQUINERO, Leticia; CARVALHO, Priscila R.; SIQUEIRA, Scheila; VELLOSO, Elvira R. P.
  • article 5 Citação(ões) na Scopus
    MR 4log and low levels of NK cells are associated with higher molecular relapse after imatinib discontinuation: Results of a prospective trial
    (2021) SEGURO, Fernanda S.; MACIEL, Felipe V. R.; SANTOS, Fernanda M.; ABDO, Andre N. R.; PEREIRA, Thales D. M.; NARDINELLI, Luciana; ROCHA, Vanderson; BENDIT, Israel
    Background: Treatment-free survival (TFS) in chronic myeloid leukemia (CML) is a new goal. This prospective study aims to evaluate imatinib discontinuation's feasibility and safety in patients with deep molecular response MR4 (BCR-ABL1 < 0.01 % IS). Methods: Study was approved by the ethical committee and registered at Clinicaltrials.gov (NCT03239886). Incluision criteria were: age >= 18y, chronic phase, first-line imatinib for 36 months, MR4 for 12 months, no previous transplant or resistance. Imatinib was resumed when two samples confirmed the loss of MMR. The primary endpoint was molecular recurrence-free survival (MRFS) at 24 months. Lymphocyte subpopulations were counted in peripheral blood before discontinuation. Results: 31 patients were included from Dec/2016 until Oct/2017. Median age was 54years, 58 % male, 58 % low Sokal, 65 % b3a2 transcripts, and 61 % were in MR4.5. Imatinib therapy's median time was 9.7y (3-14.9 y), median time of MR4 was 6.9y (1.6-10.3y). MRFS at 24 months was 55 % (95 % CI 39-75). Thirteen patients relapsed, 46 % after six months of discontinuation, and all patients recovered MMR. Median time to recover MMR was one month. MR4.5 was the only factor associated with MRFS. NK cells proportion at baseline was lower in patients with only MR4 who relapsed after discontinuation. Conclusion: With a median duration of sustained MR4 above five years, as recommended by most TKI discontinuation guidelines, the TFS was similar to previous studies. Only MR4.5 was associated with lower risk of relapse. Further studies are needed to evaluate whether patients with only MR4 and low NK cell levels are suitable for discontinuation.
  • conferenceObject
    Chronic Myeloid Leukemia: Comparison of Survival between Pregnant and Non-Pregnant Women
    (2020) GHELFOND, Giovanna Iantevi; SANTOS, Fernanda; SEGURO, Fernanda S.; ABDO, Andre; PEREIRA, Thales; MACIEL, Felipe V. R.; ALVES, Lucas B. O.; BENDIT, Israel; ROCHA, Vanderson; REGO, Eduardo M.
  • article 0 Citação(ões) na Scopus
    Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response
    (2023) FERREIRA, Amanda Pifano Soares; SEGURO, Fernanda Salles; ABDO, Andre Ramires Neder; SANTOS, Fernanda Maria; MACIEL, Felipe Vieira Rodrigues; NARDINELLI, Luciana; GIORGI, Ricardo Rodrigues; RUIZ, Antonio Roberto Lancha; FERREIRA, Milton Pifano Soares; REGO, Eduardo Magalhaes; ROCHA, Vanderson; BENDIT, Israel
    Introduction Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the Philadelphia (Ph) chromosome. After the introduction of imatinib mesylate (IM) in 2000, the natural history of the disease changed. Data on the treatment of CML with IM are from randomized clinical trials. Establishing whether these results can be reproduced or if caution is needed when extrapolating data to the general population with CML is essential. Objectives To evaluate the molecular response (MR) in patients with chronic-phase CML (CML-CP) not included in clinical studies and correlate them with the responses obtained in clinical trials. Methods Between January 2007 and January 2017, 227 patients newly diagnosed with CML-CP treated with IM as first-line treatment were included. This study is an observational, retrospective, and single-center study. Results At a median follow-up time of 7.3 years, 60.3% of the 227 patients who started IM were still on IM. Early molecular response (EMR) at 3 and 6 months was achieved by 74.2% and 65%, respectively. The median time to a MMR was nine months. The MR4.0 and MR4.5 were 67.2% and 51.1%, respectively. The overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) of the patients who exclusively used IM were 91%, 91%, and 85.1%, respectively. Conclusion The results presented are similar to those described in prospective and randomized trials, demonstrating that the outcomes are reproducible in the real world. EMR at 3 and 6 months reflects better long-term responses, including higher rates of deeper molecular responses. Considering treatment costs, the absence of literature evidence of an impact on overall survival demonstrated by first-line second-generation tyrosine kinase inhibitors (TKIs), and the global OS of 85.8%, imatinib mesylate (IM) is still an excellent therapeutic option.
  • article 2 Citação(ões) na Scopus
    Impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia
    (2022) SANTOS, Fernanda Maria; GHELFOND, Giovanna; SEGURO, Fernanda Salles; ABDO, Andre Neder R.; DALESSANDRO, Thales; MACIEL, Felipe Vieira R.; BASSOLLI, Lucas; ROCHA, Vanderson; BENDIT, Israel
  • conferenceObject
    Comparison Between R-CHOP Vs R-CHOP Plus Etoposide in Untreated Patients with Primary Mediastinal B-Cell Lymphoma: Preliminary Findings
    (2014) MACIEL, Felipe Vieira Rodrigues; SZOR, Roberta Shcolnik; LEVY, Debora; SANTUCCI, Rodrigo; PEREIRA, Juliana
  • conferenceObject
    Lymphocyte Subpopulations and Expression of Immune Checkpoint Receptors PD-1 and Tim-3 in Patients with Chronic Myeloid Leukemia in a Discontinuation Trial
    (2019) SEGURO, Fernanda S.; MACIEL, Felipe V. R.; LOPES, Guilherme O.; NARDINELLI, Luciana; ROCHA, Vanderson; BENDIT, Israel
  • conferenceObject
  • article 0 Citação(ões) na Scopus
    Real-world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response (Apr, 10.1007/s00277-023-05189-3, 2023)
    (2023) FERREIRA, Amanda Pifano Soares; SEGURO, Fernanda Salles; ABDO, Andre Ramires Neder; SANTOS, Fernanda Maria; MACIEL, Felipe Vieira Rodrigues; NARDINELLI, Luciana; GIORGI, Ricardo Rodrigues; RUIZ, Antonio Roberto Lancha; FERREIRA, Milton Pifano Soares; REGO, Eduardo Magalhaes; ROCHA, Vanderson; BENDIT, Israel
  • bookPart
    Leucemia mieloide crônica
    (2016) SEGURO, Fernanda Salles; MEDINA, Andrezza Bertolaci; ABDO, André Neder R.; MACIEL, Felipe Vieira Rodrigues; BENDIT, Israel